Adverse event category | Artz | Durolane |
---|---|---|
(5 × 2.5 ml) | (1 × 3 ml, 4 × sham) | |
( n  = 174) | ( n  = 175) | |
Patients with at least one treatment-emergent adverse event | 74 (42.5%) | 83 (47.4%) |
Treatment-related adverse event | 17 (9.8%) | 23 (13.1%) |
Treatment adjustment | 1 (0.6%) | 0 |
Treatment permanent stop | 1 (0.6%) | 0 |
Importanta | 2 (1.1%) | 0 |
Severe | 8 (4.6%) | 6 (3.4%) |
Seriousb | 6 (3.4%) | 3 (1.7%) |
All treatment-related adverse eventsc | 17 (9.8%) | 23 (13.1%) |
Musculoskeletal and connective tissue disorders | 16 (9.2%) | 18 (10.3%) |
Arthralgia | 13 (7.5%) | 15 (8.6%) |
Joint swelling | 3 (1.7%) | 3 (1.7%) |
Arthropathy | 0 | 1 (0.6%) |
Epicondylitis | 1 (0.6%) | 0 |
Joint effusion | 0 | 1 (0.6%) |
Limb discomfort | 1 (0.6%) | 0 |
Muscular weakness | 0 | 1 (0.6%) |
Musculoskeletal discomfort | 0 | 1 (0.6%) |
Myalgia | 1 (0.6%) | 0 |
Pain in extremity | 0 | 1 (0.6%) |
Skin and subcutaneous tissue disorders | 0 | 1 (0.6%) |
Erythema | 0 | 1 (0.6%) |